Norgine
24.01.2025 - 19:00
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome ...
To the press release of Norgine07.01.2025 - 01:00
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This ...
To the press release of Norgine02.10.2024 - 15:01
London (ots/PRNewswire) - Norgine (the "Company"), a leading European specialty pharmaceutical company, has today announced the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective from 1 January 2025. Current CEO, ...
To the press release of Norgine18.03.2024 - 08:00
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing ...
To the press release of Norgine11.09.2023 - 09:01
Amsterdam (ots/PRNewswire) - Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment of Saulo Martiniano as its new Chief Operating Officer (COO). Saulo joins ...
To the press release of Norgine 
